BioSpace News Archive

BrainsWay Ltd. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) allowing the Company to market its Deep Transcranial Magnetic Stimulation (Deep TMS™) System

BridgeBio Pharma, Inc. today announced that it has added three new independent directors to its board

Crescita Therapeutics Inc. and STADA MENA DWC-LLC announced an exclusive commercialization and development license agreement for the exclusive rights to the topical anaesthetic cream Pliaglis®, in 15 countries in the Middle East and North Africa region, comprising: Saudi Arabia, the United Arab Emirates, Kuwait, Oman, Qatar, Bahrain, Jordan, Lebanon, Egypt, Algeria, Morocco, Tunisia, Iraq, Libya and Yemen.

Stryker announced that after an outstanding thirty-one-year career at Stryker, Timothy J. Scannell, President and Chief Operating Officer has notified the company of his intent to retire on March 31, 2023.

Galecto, Inc. today announced the treatment of the first patient in a Phase 2a trial of its oral LOXL2 inhibitor GB2064 in myelofibrosis.

Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare retinal diseases, announced the addition of Yehia Hashad, MD to its Board of Directors.

CM Life Sciences II and Twist Bioscience Corporation today announced a collaboration aimed at creating novel antibodies and enabling innovative drug discovery based on key disease biomarkers.

TrialJectory (“the Company”), announced today results from a proprietary survey highlighting that, while an overwhelming majority of cancer patients surveyed (90 percent) understand the importance of genetic testing for achieving better clinical outcomes, less than half (46 percent) reported having undergone Next-Generation Sequencing (NGS),

Urovant Sciences, Inc., a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced key data for GEMTESA® (vibegron) 75 mg to be presented at the 2021 Annual Meeting of the American Urological Association (AUA2021).

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Patent and Trademark Office has issued the first U.S. patent for its novel ovarian cancer vaccine technology.